SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

BIOA

BioAge Labs, Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The positive biomarker data for BGE-102 supports its potential as a best-in-class oral NLRP3 inhibitor, with upcoming Phase 2a readouts in 2026 serving as key catalysts. The expanded indication into DME diversifies clinical risk. While fundamentals remain pre-revenue and loss-making, the strong cash position de-risks near-term execution. Traders should monitor Phase 2a initiation and data timelines as potential upside triggers.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.11
T+0 close · Mar 24, 2026 · via day close
Latest settled
+28.93%
T+60 · $20.77
Vs SPY
+14.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $16.11entry
  2. T+1 · 8mo ago +1.86%α +1.30% · $16.41
  3. T+5 · 8mo ago +8.57%α +8.99% · $17.49
  4. T+20 · 7mo ago +13.97%α +5.07% · $18.36
  5. T+60 · 5mo ago +28.93%α +14.60% · $20.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positive Phase 1 data for its NLRP3 inhibitor BGE-102, expansion into ophthalmology, and completion of a $132.3 million follow-on offering. The company now has $285.1 million in cash, funding operations through 2029. While collaboration revenue rose to $9.0 million, R&D and G&A expenses increased, resulting in a net loss of $80.6 million.

Key Financial Metrics

Revenue
$9.0M
EPS
$-2.24
Deal Value
$132.3M

Key Facts

  • Positive interim Phase 1 data for BGE-102 showed 86% median reduction in hsCRP, 58% in IL-6, and 30% in fibrinogen in obese patients with elevated inflammation.
  • Phase 2a proof-of-concept trial in cardiovascular risk to initiate in 1H 2026; data expected in 2H 2026.
  • BGE-102 program expanded into diabetic macular edema (DME), with Phase 1b/2a trial planned for mid-2026.
  • Completed upsized follow-on offering raising $132.3 million in gross proceeds, strengthening cash position.
  • Cash, cash equivalents, and marketable securities totaled $285.1 million as of December 31, 2025, sufficient to fund operations through 2029.
  • Collaboration revenue was $9.0 million in 2025 (vs. $0 in 2024), driven by the Novartis partnership.
  • R&D expenses rose to $73.9 million (from $59.0 million in 2024), primarily due to BGE-102 and APJ agonist programs, partially offset by termination of azelaprag.
  • Net loss was $80.6 million in 2025 ($2.24 per share), compared to $71.1 million ($6.63 per share) in 2024.

Financial Impact

Revenue increased by $9.0 million due to Novartis collaboration, but R&D and G&A expenses rose by $14.9M and $8.6M respectively, leading to a larger net loss. However, the $132.3M capital raise significantly extends runway.

revenuer_and_d_expensenet_losscash_positiondilution

Risk Factors

  • Clinical development risk: BGE-102 is still in early stages; Phase 2a data may not confirm efficacy.
  • Dilution from the follow-on offering: 6.8M shares issued, increasing share count by ~18%.
  • High cash burn: Despite extended runway, R&D spending is accelerating, and future financings may be needed before commercialization.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261303

Track record

11 reports on BIOA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.24 −4.73% settles Nov 23
  2. Nov 5, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202610d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.24 −1.87% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.24 −74.43% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.24 −70.87% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.24 −71.46% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.24 −73.28% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.24 −70.45% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Viewing Entry $16.11 to $17.49 Now $5.24 −67.47% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.24 −74.39% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Open · Closes in 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026